All articles by Vishnu Priyan

Vishnu Priyan

Armata concludes Phase Ib/IIa Pseudomonas aeruginosa infection therapy trial

The company anticipates topline findings from the trial in the first quarter of next year.

Health Canada grants clearance for Ceapro’s anti-inflammatory therapy trial

Participant recruitment in the trial is expected to begin early next year.

US FDA grants approval for Gradalis’ Phase III ovarian cancer trial

Progression-free survival is the primary endpoint while overall survival is a crucial secondary endpoint of the trial.

Italy grants clearance for Moleculin’s Phase I/II leukaemia therapy trial

The treatment of the first subject in Italy is expected in the first quarter of next year.

Beckley Psytech begins Phase IIa treatment resistant depression trial

Anticipated to enrol the first subject in January next year, the trial will evaluate the impact of one dose of BPL-003.

Kira gets clearance for bifunctional biologic trial in China, Australia

The trials will assess the safety, efficacy, tolerability, PK and PD of KP104 in IgAN and C3G patients.

Imago doses first subject in Phase II myelofibrosis treatment trial

The trial will evaluate the safety and efficacy of bomedemstat plus ruxolitinib for 28 days.

Biocon commences Phase II trial of ulcerative colitis therapy

The trial will enrol up to 90 subjects at multiple trial sites in India.

Synaptogenix reports data from Phase II Alzheimer’s trial

According to the findings, the trial failed to meet the primary endpoint with statistical significance.

Frequency doses first patient in Phase Ib sensorineural hearing loss trial

The company plans to report clinical data from the trial in the second half of next year.